TrialPsychiatry and clinical neurosciences2024

Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.

Masaki Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.